Last reviewed · How we verify
Placebo to Fosfomycin
Fosfomycin is a broad-spectrum antibiotic that inhibits bacterial cell wall synthesis by blocking peptidoglycan cross-linking.
Fosfomycin is a broad-spectrum antibiotic that inhibits bacterial cell wall synthesis by blocking peptidoglycan cross-linking. Used for Uncomplicated urinary tract infections, Acute cystitis, Complicated urinary tract infections (in combination therapy).
At a glance
| Generic name | Placebo to Fosfomycin |
|---|---|
| Sponsor | University Medical Center Goettingen |
| Drug class | Antibiotic (phosphonic acid derivative) |
| Target | MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Fosfomycin irreversibly inhibits the enzyme MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), which catalyzes an early step in peptidoglycan biosynthesis. This disruption of cell wall formation leads to bacterial cell death. The drug is effective against both gram-positive and gram-negative bacteria, including many resistant strains.
Approved indications
- Uncomplicated urinary tract infections
- Acute cystitis
- Complicated urinary tract infections (in combination therapy)
Common side effects
- Diarrhea
- Nausea
- Headache
- Vaginitis
Key clinical trials
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
- Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial (PHASE4)
- Observational Follow-up Study of REGATTA
- Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients (PHASE4)
- Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs (PHASE3)
- Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia (PHASE2)
- Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E (PHASE2, PHASE3)
- Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Fosfomycin CI brief — competitive landscape report
- Placebo to Fosfomycin updates RSS · CI watch RSS
- University Medical Center Goettingen portfolio CI